Cover Image
市場調查報告書

家族性大腸瘜肉症:開發中產品分析

Familial Adenomatous Polyposis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200943
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
家族性大腸瘜肉症:開發中產品分析 Familial Adenomatous Polyposis - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 37 Pages
簡介

所謂家族性腺瘤息肉症(FAP)又稱家族性大腸多發性瘜肉症,是以大腸及直腸癌為特徵的遺傳性疾病。家族性腺瘤息肉症的典型最早會在青少年期結腸內便會出現複數非癌性(良性)腫瘤。只要不去除結腸,息肉便會惡性化(癌化)。常見的症狀有直腸出血、排便習慣的惡化、腹痛、血球數低、原因不明的體重減輕等。

本報告提供家族性大腸瘜肉症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

家族性大腸瘜肉症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Marina Biotech, Inc.
  • S.L.A. Pharma AG
  • Cancer Prevention Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • icosapent
  • eflornithine hydrochloride + sulindac
  • aspirin
  • CEQ-508
  • CEQ-501

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9591IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 2, 1 and 4 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Familial Adenomatous Polyposis - Overview
    • Familial Adenomatous Polyposis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Familial Adenomatous Polyposis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
    • Cancer Prevention Pharmaceuticals Inc
    • Marina Biotech Inc
    • Thetis Pharmaceuticals LLC
  • Familial Adenomatous Polyposis - Drug Profiles
    • (celecoxib + lisinopril) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (eflornithine hydrochloride + sulindac) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLX-181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icosapent ethyl - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pyrvinium pamoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Familial Adenomatous Polyposis - Dormant Projects
  • Familial Adenomatous Polyposis - Discontinued Products
  • Familial Adenomatous Polyposis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals' Phase 3 Trial for Familial Adenomatous Polyposis Patients
      • Mar 29, 2017: Marina Biotech to Present Data on IT-102 at 2017 American Association for Cancer Research Annual Meeting
      • Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
      • Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
      • Jan 27, 2016: Thetis Pharmaceuticals Awarded Key Patent for TP-252
      • Jan 19, 2016: Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
      • Oct 15, 2015: Thetis Pharmaceuticals Presents at BIO Investor Forum in San Francisco
      • Aug 04, 2015: Thetis Receives Notice of Allowance for Patent Covering Pharmaceutical Composition of Novel Mineral Amino Acid Derivative TP-252
      • Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment
      • Dec 08, 2011: S.L.A. Pharma Announces Plans For Alfa Phase III Orphan Drug Program For Familial Adenomatous Polyposis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Familial Adenomatous Polyposis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
  • Familial Adenomatous Polyposis - Pipeline by Marina Biotech Inc, H2 2017
  • Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H2 2017
  • Familial Adenomatous Polyposis - Dormant Projects, H2 2017
  • Familial Adenomatous Polyposis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Familial Adenomatous Polyposis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top